Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
Status:
Terminated
Trial end date:
2001-04-14
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of
severe extrarenal complications observed in children with acute stage E. coli-associated
hemolytic uremic syndrome.
II. Determine the effect of SYNSORB Pk therapy on the need for the duration of dialysis in
these patients.
III. Determine the effect of SYNSORB Pk therapy on the recovery of renal function and
resolution of urinary abnormalities in these patients.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)